Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation
Company Logo

Destroying Cancer at the Speed of Light®

Clinical Study Underway (75 of 100 Patients Treated)
Expected to complete enrollment at the end of 2024
Expected to complete study at the end of 2026


Bullboard - Investor Discussion Forum Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  TLTFF

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called... see more

TSXV:TLT - Post Discussion

Theralase Technologies Inc. > Full-time bullboard is organized and transparent - IMHO...
View:
Post by SouthernTierTom on May 12, 2022 7:48pm

Full-time bullboard is organized and transparent - IMHO...

Funny how none of them will acknowledge the fact that this company has not participated in an invester focussed bio-tech roadshow or conference in like 2 years?

Do correct me if I'm wrong, please do share the show and the date I've missed.

Today, Bellus, a phase 2 chronic cough play went up near TRIPLE the TOTAL market cap of this company on news of a 14M 1/4ly loss.

They do have 234M in the bank, BUt their market cap in in excess of 1 BILLION..about 20 TIMES the value of this potential "cancer cure" as per advertisied here on the bullboared.  I can't or won't make that claim until Bethesda "stamps it"

UHN, stellar science, tight ownership, favorable and focussed raises with active bullboards..Hmmm?  been there done that Canada..stay tuned!

I smell something people like..maybe tooo much ; - )

Money, money, money .....focussed raises allow for even more control.  How do we fund our "skinny kitty"?

Focus on the facts..NOT on Knoxt telling you the bullboard is most read and "most worked"

GLTA!
Comment by ScienceFirst on May 12, 2022 9:59pm
Funny that TractorTom is unable to show us a competitor that has better numbers than TLT.
Comment by Lesalpes29 on May 13, 2022 5:49am
Probably a post from ST... ignored since a long time. Well organized BB of course. We meet every 2 days to plan what we are going to post day after day! If you dont like the story And the BB you can go away. We are going to miss you! 
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.


Connect with V.TLT



Investor Presentation

The Road to Saving Lives: Clinical Study Underway

  • Clinical Study with 75 of 100 Patients Treated (Enrollment to be completed by end of 2024, with study completed by end of 2026)
     
  • Ground Floor Investment Opportunity in Multi-Billion Dollar Industry
     
  • Best-in-class treatment for NMIBC (according to interim clinical data)
     
  • NMIBC (Non-Muscle-Invasive Bladder Cancer)
     

FACT SHEET

View the Presentation

The Watchlist

The Watchlist
{{currentVideo.videoCaption}}
< Previous Video {{moreVideoText}} Next Video >

Investment Opportunity

The Road to Saving Lives: Clinical Study Underway

  • Clinical Study with 72 of 100 Patients Treated (Enrollment to be completed by end of 2024, with study completed by end of 2026)
     
  • Ground Floor Investment Opportunity in Multi-Billion Dollar Industry
     
  • Best-in-class treatment for NMIBC (according to interim clinical data)
     
  • NMIBC (Non-Muscle-Invasive Bladder Cancer)
     

Facebook

Contact Us

Address:
41 Hollinger Road
Toronto, ON M4B 3G4
Canada

Toll Free:
1-866-THE-LASE (843-5273)
Local Phone:
416-699-LASE (5273)

Email:
info@theralase.com

Fax:
416-699-5250